{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:39:21Z","timestamp":1772120361099,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DA14211"],"award-info":[{"award-number":["R01-DA14211"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-GM63674"],"award-info":[{"award-number":["R01-GM63674"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DA25931"],"award-info":[{"award-number":["R01-DA25931"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24-DA00417"],"award-info":[{"award-number":["K24-DA00417"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.bcp.2015.03.007","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T00:28:51Z","timestamp":1428712131000},"page":"115-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Influence of HIV antiretrovirals on methadone N-demethylation and transport"],"prefix":"10.1016","volume":"95","author":[{"given":"Scott D.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gadel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Friedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Crafford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen J.","family":"Regina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan D.","family":"Kharasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.03.007_bib0290","first-page":"493","article-title":"Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010","volume":"61","author":"Paulozzi","year":"2012","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.bcp.2015.03.007_bib0295","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2174\/138920012802850119","article-title":"The cellular pharmacokinetics of HIV protease inhibitors: current knowledge and future perspectives","volume":"13","author":"Zha","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2015.03.007_bib0300","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11904-010-0048-2","article-title":"Methadone, buprenorphine, and street drug interactions with antiretroviral medications","volume":"7","author":"Gruber","year":"2010","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.bcp.2015.03.007_bib0305","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1521-0391.2009.00010.x","article-title":"Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs","volume":"19","author":"Khalsa","year":"2010","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.bcp.2015.03.007_bib0310","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0315","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/ecp.13.18","article-title":"A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice","volume":"6","author":"Bruce","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0320","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1016\/j.bcp.2015.03.007_bib0325","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0330","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","article-title":"Enantiomeric metabolic interactions and stereoselective human methadone metabolism","volume":"321","author":"Totah","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0335","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2015.03.007_bib0340","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0345","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0350","first-page":"1347","article-title":"The involvement of cytochrome P450 3A4 in the N-demethylation of L-a-acetylmethadol (LAAM), norLAAM, and methadone","volume":"25","author":"Moody","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0355","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2015.03.007_bib0360","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0365","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","article-title":"Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment","volume":"67","author":"Shiran","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0370","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of cytochrome P450 3A (CYP3A) by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0375","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1742-7843.2006.pto_249.x","article-title":"Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro","volume":"98","author":"Granfors","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0380","first-page":"257","article-title":"Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors","volume":"26","author":"Iribarne","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0385","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics. I. Evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0390","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1124\/dmd.113.053991","article-title":"Cytochrome P4503A does not mediate the interaction between methadone and ritonavir\/lopinavir","volume":"41","author":"Kharasch","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1213\/ANE.0b013e3181fec9a3","article-title":"Intraoperative methadone: rediscovery, reappraisal, and reinvigoration","volume":"112","author":"Kharasch","year":"2011","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.bcp.2015.03.007_bib0400","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cpdd.137","article-title":"Drug interactions with methadone: time to revise the product label","volume":"3","author":"Greenblatt","year":"2014","journal-title":"Clin. Pharm. Drug Dev."},{"key":"10.1016\/j.bcp.2015.03.007_bib0405","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0410","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1124\/dmd.111.038646","article-title":"Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6 and 2C9 by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0415","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1517\/17425255.4.7.837","article-title":"An update on metabolism studies using human hepatocytes in primary culture","volume":"4","author":"Gomez-Lechon","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0420","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1213\/ANE.0b013e3182918252","article-title":"Mechanism of autoinduction of methadone N-demethylation in human hepatocytes","volume":"117","author":"Campbell","year":"2013","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.bcp.2015.03.007_bib0425","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bcp.2010.08.008","article-title":"Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1","volume":"80","author":"Mandery","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0430","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/mp050088t","article-title":"A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line","volume":"3","author":"Xiao","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2015.03.007_bib0435","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1124\/dmd.109.027029","article-title":"In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America perspective","volume":"37","author":"Chu","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0440","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/187231210792928224","article-title":"A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with \u00df-naphthoflavone, phenobarbital and rifampicin","volume":"4","author":"Zhang","year":"2010","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.bcp.2015.03.007_bib0445","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0450","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2015.03.007_bib0455","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1124\/dmd.108.022046","article-title":"Substrate-dependent breast cancer resistance protein (Bcrp1\/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design","volume":"37","author":"Giri","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0460","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1124\/dmd.109.028605","article-title":"Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes","volume":"37","author":"Moody","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0465","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","article-title":"Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions","volume":"35","author":"Dixit","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0470","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/QAI.0b013e3181f52f0c","article-title":"Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans","volume":"55","author":"Sv\u00e4rd","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bcp.2015.03.007_bib0475","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/bdd.1788","article-title":"Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS\/MS cocktail assays and RT-PCR","volume":"33","author":"Liu","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0480","first-page":"100","article-title":"Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion","volume":"29","author":"Hesse","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0485","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s002280000125","article-title":"Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole","volume":"56","author":"von Moltke","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0490","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350901400514","article-title":"Maraviroc: pharmacokinetics and drug interactions","volume":"14","author":"Abel","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0495","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1128\/AAC.01600-07","article-title":"Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir","volume":"52","author":"Kharasch","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2015.03.007_bib0500","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1345\/aph.1K615","article-title":"Induction effects of ritonavir: implications for drug interactions","volume":"42","author":"Foisy","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2015.03.007_bib0505","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000107104","article-title":"In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites","volume":"80","author":"Crettol","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.bcp.2015.03.007_bib0510","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1017\/S1461145709990848","article-title":"Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)","volume":"13","author":"Tournier","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0515","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00213-003-1718-1","article-title":"Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice","volume":"173","author":"Wang","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bcp.2015.03.007_bib0520","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2125.2003.02053.x","article-title":"The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone","volume":"57","author":"Kharasch","year":"2004","journal-title":"Br J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2015.03.007_bib0525","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/ALN.0000000000000391","article-title":"Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics","volume":"121","author":"Meissner","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2015.03.007_bib0530","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment","volume":"80","author":"Crettol","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.03.007_bib0535","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","article-title":"ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence","volume":"17","author":"Levran","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2015.03.007_bib0540","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.12.009","article-title":"Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity","volume":"101","author":"Kharasch","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.bcp.2015.03.007_bib0545","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/1568026611313070008","article-title":"Medicinal chemistry design principles for liver targeting through OATP transporters","volume":"13","author":"Tu","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcp.2015.03.007_bib0550","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/jps.22655","article-title":"Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors","volume":"100","author":"Griffin","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2015.03.007_bib0555","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/dmd.112.050278","article-title":"Which metabolites circulate","volume":"41","author":"Loi","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2015.03.007_bib0560","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugalcdep.2012.05.009","article-title":"Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers","volume":"126","author":"Vourvahis","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.bcp.2015.03.007_bib0565","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/ALN.0b013e3182423478","article-title":"Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A)","volume":"116","author":"Kharasch","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2015.03.007_bib0570","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of cytochrome P4502B6 in methadone metabolism and clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"J. Clin. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215001525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215001525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T06:02:02Z","timestamp":1747893722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0006295215001525"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.03.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725402891.793507974","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of HIV antiretrovirals on methadone N-demethylation and transport","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}